Cargando…

Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia

BACKGROUND: Streptococcus pneumoniae is the leading cause of community-acquired pneumonia (CAP). High global incidence of macrolide and penicillin resistance has been reported, whereas fluoroquinolone resistance is uncommon. Current guidelines for suspected CAP in patients with co-morbidity factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Endimiani, Andrea, Brigante, Gioconda, Bettaccini, Alessia A, Luzzaro, Francesco, Grossi, Paolo, Toniolo, Antonio Q
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1308815/ https://www.ncbi.nlm.nih.gov/pubmed/16307682 http://dx.doi.org/10.1186/1471-2334-5-106

Ejemplares similares

Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system
por: Brigante, Gioconda R, et al.
Publicado: (2007)

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
por: Tanaseanu, Cristina, et al.
Publicado: (2009)

Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase
por: Endimiani, Andrea, et al.
Publicado: (2006)

Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin
por: Ramirez, Julio A, et al.
Publicado: (2012)

Culture of skeletal myoblasts from human donors aged over 40 years: dynamics of cell growth and expression of differentiation markers
por: Baj, Andreina, et al.
Publicado: (2005)

Tigecycline Versus Levofloxacin in Hospitalized Patients With Community-Acquired Pneumonia: An Analysis of Risk Factors
por: Dartois, Nathalie, et al.
Publicado: (2013)

Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes
por: Bettaccini, Alessia A, et al.
Publicado: (2005)

Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines
por: Principi, Nicola, et al.
Publicado: (2016)

Current Concepts of Severe Pneumococcal Community-acquired Pneumonia
por: Luján, M., et al.
Publicado: (2007)

Current Concepts of Severe Pneumococcal Community-acquired Pneumonia
por: Luján, M., et al.
Publicado: (2007)

Pneumococcal Aetiology and Serotype Distribution in Paediatric Community-Acquired Pneumonia
por: De Schutter, Iris, et al.
Publicado: (2014)

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis
por: Zhao, Mingye, et al.
Publicado: (2022)

Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study
por: Yadegarynia, Davood, et al.
Publicado: (2022)

Prognostic value of pneumococcal urinary antigen test in community-acquired pneumonia
por: Kim, Byunghyun, et al.
Publicado: (2018)

Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU
por: Belkhouja, Khairallah, et al.
Publicado: (2011)

Severe Hyponatremia due to Levofloxacin Treatment for Pseudomonas aeruginosa Community-Acquired Pneumonia in a Patient with Oropharyngeal Cancer
por: Mocan, Mihaela, et al.
Publicado: (2016)

The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
por: Shen, Ching-Fen, et al.
Publicado: (2020)

1149. Contribution of S.pneumoniae Serotypes in Adults with Invasive Pneumococcal Disease (IPD) and Pneumococcal Community-acquired Pneumonia (pCAP)
por: Apodaca, Kevin, et al.
Publicado: (2023)

In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia
por: Grijalva, Carlos G., et al.
Publicado: (2015)

Health related quality of life in patients with community-acquired pneumococcal pneumonia in France
por: Andrade, Luiz Flavio, et al.
Publicado: (2018)

COMMUNITY ACQUIRED PNEUMOCOCCAL PNEUMONIA IN NORTHWESTERN NIGERIA: EPIDEMIOLOGY, ANTIMICROBIAL RESISTANCE AND OUTCOME
por: Iliyasu, Garba, et al.
Publicado: (2017)

The impact of pneumococcal conjugate vaccine on community-acquired pneumonia hospitalizations in children with comorbidity
por: Sterky, Ellinor, et al.
Publicado: (2017)

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults
por: Isturiz, Raul, et al.
Publicado: (2015)

Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
por: Noreddin, Ayman M, et al.
Publicado: (2011)

Overview of Community-Acquired Pneumonia and the Role of Inflammatory Mechanisms in the Immunopathogenesis of Severe Pneumococcal Disease
por: Steel, Helen C., et al.
Publicado: (2013)

Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children
por: da Silva, Sandra Rodrigues, et al.
Publicado: (2016)

Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2018)

Community acquired paediatric pneumonia; experience from a pneumococcal vaccine- naive population
por: Kudagammana, Sanath Thushara, et al.
Publicado: (2020)

Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study
por: Krueger, Paul, et al.
Publicado: (2010)

Cardiovascular Complications in Community-Acquired Pneumonia
por: Desai, Antonio, et al.
Publicado: (2022)

Comparison of levofloxacin (L) and cefotaxime (C) combined with ofloxacin (O) for treatment of severe community-acquired pneumonia (CAP) in the intensive care unit
por: Leroy, O, et al.
Publicado: (2004)

The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials
por: Chang, Shen-Peng, et al.
Publicado: (2019)

Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
por: Khan, Alina S, et al.
Publicado: (2023)

1460. Community-Acquired Bacteremic Pneumonia in Post-pneumococcal Vaccination Era in a Pediatric Hospital
por: Gentile, Angela, et al.
Publicado: (2018)

Incidence of Antibiotic Treatment Failure in Patients with Nursing Home-Acquired Pneumonia and Community Acquired Pneumonia
por: Lopes, Mariana, et al.
Publicado: (2021)

Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease
por: Torres, Antoni, et al.
Publicado: (2015)

Multicenter prospective study on the prevalence of colistin resistance in Escherichia coli: relevance of mcr-1-positive clinical isolates in Lombardy, Northern Italy
por: Principe, Luigi, et al.
Publicado: (2018)

Time Trend of the Sensitivity of the Pneumococcal Urinary Antigen Test for Diagnosing Pneumococcal Community-Acquired Pneumonia: An Analysis of 15-Year, Prospective Cohort Data
por: Ito, Akihiro, et al.
Publicado: (2021)

Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience
por: Baldo, Vincenzo, et al.
Publicado: (2016)

A model for predicting bacteremia in patients with community-acquired pneumococcal pneumonia: a retrospective observational study
por: Washio, Yasuyoshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8khoc5tl7kll0itlkm1e3g2s9j